These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11480395)

  • 21. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.
    Markopoulos C; Polychronis A; Zobolas V; Xepapadakis G; Papadiamantis J; Koukouras D; Lappas H; Gogas H
    Breast Cancer Res Treat; 2005 Sep; 93(1):61-6. PubMed ID: 16184460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer.
    Love RR; Newcomb PA; Wiebe DA; Surawicz TS; Jordan VC; Carbone PP; DeMets DL
    J Natl Cancer Inst; 1990 Aug; 82(16):1327-32. PubMed ID: 2199681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer.
    Montagnani A; Gonnelli S; Cadirni A; Caffarelli C; Del Santo K; Pieropan C; Campagna MS; Montomoli M; Petrioli R; Nuti R
    Eur J Intern Med; 2008 Dec; 19(8):592-7. PubMed ID: 19046724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
    Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
    Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study.
    Hong N; Yoon HG; Seo DH; Park S; Kim SI; Sohn JH; Rhee Y
    Eur J Cancer; 2017 Sep; 82():103-114. PubMed ID: 28651157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tamoxifen therapy and hepatic steatosis.
    Coskun U; Törüner FB; Günel N
    Neoplasma; 2002; 49(1):61-4. PubMed ID: 12044063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Duration of tamoxifen effect on lipidemic profile of postmenopausal breast cancer patients following deprivation of treatment.
    Markopoulos C; Chrissochou M; Antonopoulou Z; Xepapadakis G; Papadiamantis J; Tzoracoleftherakis E; Gogas H
    Oncology; 2006; 70(4):301-5. PubMed ID: 17047401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group.
    Tormey DC; Gray R; Falkson HC
    J Natl Cancer Inst; 1996 Dec; 88(24):1828-33. PubMed ID: 8961972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study.
    Hozumi Y; Suemasu K; Takei H; Aihara T; Takehara M; Saito T; Ohsumi S; Masuda N; Ohashi Y
    Ann Oncol; 2011 Aug; 22(8):1777-82. PubMed ID: 21285133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer.
    Bell R; Lewis J
    Curr Med Res Opin; 2007 May; 23(5):1045-51. PubMed ID: 17519070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen.
    Kesim MD; Aydin Y; Atis A; Mandiraci G
    Climacteric; 2008 Jun; 11(3):252-7. PubMed ID: 18568790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation.
    Johansen J; Overgaard J; Overgaard M
    Acta Oncol; 2007; 46(4):525-33. PubMed ID: 17497320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Crossover trial for lipid abnormality in postmenopausal breast cancer patients during selective estrogen receptor modulators (SERMs) administrations.
    Kusama M; Kaise H; Nakayama S; Ota D; Misaka T; Aoki T
    Breast Cancer Res Treat; 2004 Nov; 88(1):9-16. PubMed ID: 15538041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Possible deleterious effect of tamoxifen in premenopausal women with locoregional recurrence of breast cancer.
    Borner MM; Bacchi M; Castiglione M
    Eur J Cancer; 1996 Nov; 32A(12):2173-6. PubMed ID: 9014762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.
    Wright JD; Desai VB; Chen L; Burke WM; Tergas AI; Hou JY; Accordino M; Ananth CV; Neugut AI; Hershman DL
    Am J Obstet Gynecol; 2017 Jul; 217(1):59.e1-59.e12. PubMed ID: 28341383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5-7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy.
    Markopoulos C; Chrissochou M; Michailidou A; Tzoracoleftherakis E; Xepapadakis G; Papadiamantis J; Misitzis J; Zobolas V; Bafaloukos D; Gogas H
    Anticancer Drugs; 2005 Sep; 16(8):879-83. PubMed ID: 16096437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients.
    Cohen I; Figer A; Tepper R; Shapira J; Altaras MM; Yigael D; Beyth Y
    Gynecol Oncol; 1999 Feb; 72(2):202-7. PubMed ID: 10021302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
    Gnant M; Mlineritsch B; Schippinger W; Luschin-Ebengreuth G; Pöstlberger S; Menzel C; Jakesz R; Seifert M; Hubalek M; Bjelic-Radisic V; Samonigg H; Tausch C; Eidtmann H; Steger G; Kwasny W; Dubsky P; Fridrik M; Fitzal F; Stierer M; Rücklinger E; Greil R; ; Marth C
    N Engl J Med; 2009 Feb; 360(7):679-91. PubMed ID: 19213681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical efficacy of tamoxifen.
    Robert NJ
    Oncology (Williston Park); 1997 Feb; 11(2 Suppl 1):15-20. PubMed ID: 9065922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.